Vacinas
Covid-19: produção global de vacinas é desordenada e a escassez é decorrente de outros fatores além da acumulação por alguns países.
16 Nov, 2021 | 12:43h
Comentário no Twitter
Seventy countries have yet to vaccinate 10% of their populations for covid-19. What is holding up the process?
Includes a #BMJInfographic that shows whether countries producing vaccines are able to vaccinate more of their populationshttps://t.co/9Z9BtzJKR9 pic.twitter.com/zfUfSgZQtC
— The BMJ (@bmj_latest) November 2, 2021
Estudo randomizado fase 4 | Administração de vacinas contra COVID-19 (AstraZeneca ou Pfizer) concomitantemente às vacinas contra influenza sazonal em adultos é segura e preserva a resposta imune de ambas as vacinas.
15 Nov, 2021 | 14:10hAmplo estudo populacional mostra que infecção prévia por SARS-CoV-2 reduz o risco de infecção após vacina de mRNA.
15 Nov, 2021 | 14:08hComentários:
Vaccine plus previous infection may offer enhanced COVID-19 protection – CIDRAP
Comentário no Twitter
Study found prior #SARSCoV2 infection was associated with lower risk for breakthrough infection among persons receiving the SARS-CoV-2 mRNA vaccines; however, the observational study design precludes direct comparison of infection risk btwn the 2 vaccines https://t.co/1RLuKSGPjy
— JAMA (@JAMA_current) November 1, 2021
Estudo populacional no Catar mostrou que a efetividade contra doença grave, crítica ou fatal induzida pela variante Delta do SARS-CoV-2 foi de 93,4% para a vacina da Pfizer e de 96,1% para a vacina da Moderna.
15 Nov, 2021 | 14:06h
Comentário no Twitter
A study in @NatureMedicine shows that mRNA COVID-19 vaccines are highly effective at preventing severe outcomes and death caused by the SARS-CoV-2 Delta variant in Qatar despite substantially lower effectiveness at blocking infection. https://t.co/V09Ma583fy pic.twitter.com/QG2HaDsrCo
— Nature Portfolio (@NaturePortfolio) November 4, 2021
[Preprint] Risco de COVID-19 grave é raro entre pessoas com vacinação plena na Inglaterra.
15 Nov, 2021 | 14:01hComentário: Risk of severe COVID-19 is rare among fully vaccinated individuals in England – News Medical
Estudo original: Describing the population experiencing COVID-19 vaccine breakthrough following second vaccination in England: A cohort study from OpenSAFELY – medRxiv
De acordo com estudo, vacinas contra SARS-CoV-2 são seguras e imunogênicas na maioria das pessoas com câncer.
15 Nov, 2021 | 13:56hComunicado de imprensa: SARS-CoV-2 vaccines are safe and immunogenic in most people with cancer, according to study – Harvard Medical School
Estudo original: Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study – Journal of Clinical Oncology
Comentário do autor no Twitter (fio – clique para saber mais)
The CANVAX study is out in @JCO_ASCO! https://t.co/WKrU6dQIEB
Grateful to >1000 CANVAX participants, study leads ( @JustinGainor, @MGHPathology, @BalazsLab) and so many co-authors incl. @arthur_kim_ID, @KimberlyBlumen1, @joanhowMD, @dradityabardia
Much more to come!— Vivek Naranbhai, MD, PhD, DPhil (@vivek_naranbhai) November 10, 2021
Estudo randomizado | BBV152 (vacina indiana COVAXIN) tem uma eficácia geral de 77,8% contra Covid-19 sintomática em adultos.
12 Nov, 2021 | 13:51hComentário convidado: Inactivated SARS-CoV-2 vaccine (BBV152)-induced protection against symptomatic COVID-19 – The Lancet
Conteúdo relacionado: WHO issues emergency use approval for India’s Covaxin.
Comentário no Twitter
NEW—Interim data from a phase 3 trial of #BBV152, a COVID-19 vaccine developed in India, suggests it is safe and two doses offer 77.8% protection against symptomatic #COVID19. https://t.co/QWtz0AWd1X
— The Lancet (@TheLancet) November 11, 2021
Aumento da imunidade às vacinas contra COVID-19 – “Novos estudos destacam os benefícios imunológicos dos reforços da vacina contra COVID-19, mas ainda restam questões sobre como fazer o melhor uso de suprimentos globais limitados.”
12 Nov, 2021 | 13:46hBoosting immunity to COVID-19 vaccines – Nature Medicine
Mapa | O mundo segundo a cobertura vacinal contra Covid.
12 Nov, 2021 | 13:43hThe world according to covid vaccine coverage – The BMJ
Comentário no Twitter
A year since the first covid vaccines were announced, rollouts are under way all over the world—to differing degrees.
This map shows the percentage of national population to have received two doses of covid vaccinehttps://t.co/rIU3qeWXIK @munkeatlooi pic.twitter.com/zZHr1XXBe8
— The BMJ (@bmj_latest) November 11, 2021
OMS, CDC | Progresso global contra o sarampo fica ameaçado em meio à pandemia de COVID-19.
12 Nov, 2021 | 13:36hComunicado de imprensa: Global progress against measles threatened amidst COVID-19 pandemic – World Health Organization
Comentário no Twitter (fio – clique para saber mais)
While reported #measles cases have fallen compared to previous years, progress toward measles elimination continues to decline and the risk of outbreaks is mounting, according to a 🆕 report from @CDCgov & WHO.
👉 https://t.co/EjRVRexcGd pic.twitter.com/KnBU5RZn5i
— World Health Organization (WHO) (@WHO) November 10, 2021